Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accumulated Expenses (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Accumulated Expenses for 4 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 109.51% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, up 109.51% year-over-year, with the annual reading at $3.6 million for FY2025, 109.51% up from the prior year.
  • Accumulated Expenses hit $3.6 million in Q4 2025 for Taysha Gene Therapies, down from $5.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $19.0 million in Q2 2022 to a low of $1.5 million in Q1 2025.
  • Historically, Accumulated Expenses has averaged $7.8 million across 4 years, with a median of $3.7 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: plummeted 89.21% in 2023 and later surged 109.51% in 2025.
  • Year by year, Accumulated Expenses stood at $2.5 million in 2022, then surged by 37.63% to $3.5 million in 2023, then crashed by 50.56% to $1.7 million in 2024, then soared by 109.51% to $3.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for TSHA at $3.6 million in Q4 2025, $5.3 million in Q3 2025, and $1.7 million in Q2 2025.